KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash & Equivalents: 2009-2024

Historic Revenue - Interest and Investment Income for Rigel Pharmaceuticals (RIGL) over the last 2 years, with Dec 2010 value amounting to $186.7 million.

  • Rigel Pharmaceuticals' Revenue - Interest and Investment Income rose 51.21% to $166.1 million in Q4 2010 from the same period last year, while for Dec 2010 it was $445.4 million, marking a year-over-year change of. This contributed to the annual value of $186.7 million for FY2010, which is 32.65% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Revenue - Interest and Investment Income of $186.7 million as of FY2010, which was up 32.65% from $140.7 million recorded in FY2009.
  • In the past 5 years, Rigel Pharmaceuticals' Cash & Equivalents ranged from a high of $56.7 million in FY2024 and a low of $18.9 million during FY2021.
  • Moreover, its 3-year median value for Cash & Equivalents was $32.8 million (2023), whereas its average is $38.0 million.
  • Data for Rigel Pharmaceuticals' Revenue - Interest and Investment Income shows a peak YoY surged of 32.65% (in 2010) over the last 5 years.
  • Yearly analysis of 2 years shows Rigel Pharmaceuticals' Revenue - Interest and Investment Income stood at $140.7 million in 2009, then surged by 32.65% to $186.7 million in 2010.